Bli medlem
Bli medlem

Du är här


MorphoSys AG: MorphoSys and Galapagos Initiate Phase 1 Study in Joint Antibody Program MOR106

MorphoSys AG / MorphoSys and Galapagos Initiate Phase 1 Study in Joint
Antibody Program MOR106. Processed and transmitted by NASDAQ OMX Corporate
Solutions. The issuer is solely responsible for the content of this
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) and
Galapagos NV (Euronext&NASDAQ: GLPG) announced today that dosing of MOR106, a
first-in-class human monoclonal antibody, in healthy volunteers has been
initiated in a phase 1 study. MOR106 was jointly discovered by MorphoSys and
Galapagos under their collaboration, and has a novel mode of action with
potential application in inflammation.

The primary objective of the phase 1 study is to evaluate the safety and
tolerability of single doses of MOR106. The study is randomized,
double-blind, placebo-controlled and conducted in a single center in at least
56 healthy volunteers in Belgium, evaluating single ascending doses (SAD)
administered as intravenous infusion. This phase 1 study is characterized by
its adaptive design, which enables the initiation of a subsequent multiple
ascending dose (MAD) study in patients, depending on the outcome of the SAD
study in healthy volunteers.

The study's secondary objective is to characterize the pharmacokinetic profile
of MOR106 as well as monitor the occurrence of anti-drug antibodies as a
measure of immunogenicity with MOR106. Topline results of the complete study,
including the potential subsequent MAD part in patients, are expected in the
second half of 2017.

"We are delighted to see the first antibody program from our alliance with
Galapagos entering the clinical development stage. MOR106 is MorphoSys's
fifth proprietary antibody program in clinical development and the first from
our novel Ylanthia technology platform. We are excited about the growing
value and maturity of our development pipeline. The start of this very
innovative clinical development program also reflects the high value of our
ongoing collaboration with Galapagos", commented Dr. Arndt Schottelius, Chief
Development Officer of MorphoSys AG.

"The alliance with MorphoSys has produced a first-in-class candidate human
monoclonal antibody," said Piet Wigerinck, Chief Scientific Officer of
Galapagos. "MOR106 is the 10th Galapagos candidate with a new mode of action
to be brought into the clinic."

About MOR106 and the antibody collaboration
MOR106 is a human IgG1 monoclonal antibody for treatment of inflammatory
diseases. MOR106 arises from the alliance initiated by Galapagos and
MorphoSys in 2008, in which both companies contribute their core technologies
and expertise. Galapagos provides the disease-related biology including
cellular assays and targets discovered using its target discovery platform.
MorphoSys contributes its Ylanthia antibody technology to generate fully
human antibodies directed against the target and contributes full CMC
development of this compound. Galapagos and MorphoSys will continue to
equally share the research and development costs, as well as all future

About MorphoSys
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
therapeuticpipelineof more than 100 human antibody drug candidates for the
treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name
just a few. With its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys,

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®,
100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are
registered trademarks of the MorphoSys Group.

About Galapagos
Galapagos(Euronext&NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action. Our maturing pipeline comprises Phase 2, Phase 1,
pre-clinical, and discovery programs in cystic fibrosis, inflammation,
fibrosis, osteoarthritis and other indications. We have discovered and
developed filgotinib: in collaboration with Gilead we aim to bring this
JAK1-selective inhibitor for inflammatory indications to patients all over
the world. Galapagos is focused on the development and commercialization of
novel medicines that will improve people's lives. The Galapagos group,
including fee-for-service subsidiaryFidelta, has approximately 440 employees,
operating from its Mechelen, Belgium headquarters and facilities in The
Netherlands, France, and Croatia. More information

This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and
involve risks and uncertainties. Should actual conditions differ from the
Company's assumptions, actual results and actions may differ from those
anticipated, MorphoSys does not intend to update any of these forward-looking
statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications&IR

Jochen Orlowski
Associate Director Corporate Communications&IR

Alexandra Goller
Senior Manager Corporate Communications&IR

Tel: +49 (0) 89 / 899 27-404

Galapagos NV
Elizabeth Goodwin
VP IR&Corporate Communications
Tel: +1 781 460 1784

Evelyn Fox
Director Communications
Tel: +31 6 53 591 999

Media Release (PDF)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.